Cargando…

Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease

Background: Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors reduce low-density lipoprotein (LDL) cholesterol and cardiovascular event rates, yet due to their high price remain underutilized and difficult to prescribe in clinical practice. In March 2018, their price was significantly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Alex, Johnson, Drew, Banks, Joshua, Keith, Scott W., Karalis, Dean G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432238/ https://www.ncbi.nlm.nih.gov/pubmed/34501275 http://dx.doi.org/10.3390/jcm10173828

Ejemplares similares

Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia
por: Mszar, Reed, et al.
Publicado: (2023)

Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation
por: Ma, Minglu, et al.
Publicado: (2023)

Just Price for PCSK9 Inhibitors: No less, No More
por: Nasir, Khurram
Publicado: (2018)

Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease
por: Dayoub, Elias J., et al.
Publicado: (2021)

Nonadherence to lipid‐lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease
por: Desai, Nihar R., et al.
Publicado: (2022)

PCSK9 inhibitors in the prevention of cardiovascular disease
por: Latimer, James, et al.
Publicado: (2016)

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
por: Toscano, Arianna, et al.
Publicado: (2022)

Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
por: Mallya, Usha G., et al.
Publicado: (2017)

PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort
por: Small, Aeron M., et al.
Publicado: (2020)

The Effect of PCSK9 Inhibition on the Stabilization of Atherosclerotic Plaque Determined by Biochemical and Diagnostic Imaging Methods
por: Basiak, Marcin, et al.
Publicado: (2023)

PCSK9 as a therapeutic target for cardiovascular disease
por: Zhang, Pei-Ying
Publicado: (2017)

Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study)
por: LIU, Yu-Qi, et al.
Publicado: (2021)

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis
por: Li, Jiao, et al.
Publicado: (2017)

PCSK9 is minimally associated with HDL but impairs the anti-atherosclerotic HDL effects on endothelial cell activation
por: Dafnis, Ioannis, et al.
Publicado: (2022)

Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
por: Glerup, Simon, et al.
Publicado: (2017)

Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes
por: Myers, Kelly D., et al.
Publicado: (2019)

Trends in Prices of Popular Brand-Name Prescription Drugs in the United States
por: Wineinger, Nathan E., et al.
Publicado: (2019)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
por: Sobati, Saeideh, et al.
Publicado: (2020)

PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
por: Sundararaman, Sai Sahana, et al.
Publicado: (2021)

PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
por: Jia, Xiaoming, et al.
Publicado: (2022)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

FRI101 Marked Reduction In Severe Resistant Hypertriglyceridemia On PCSK9 Inhibitor
por: Kaul, Sabrina, et al.
Publicado: (2023)

Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients
por: Tóth, Štefan, et al.
Publicado: (2017)

Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque
por: Basiak, Marcin, et al.
Publicado: (2022)

Effect of PCSK9 inhibition in combination with statin therapy on intracranial atherosclerotic stenosis: A high-resolution MRI study
por: Wu, Lingshan, et al.
Publicado: (2023)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients
por: Chen, Chi-Chang, et al.
Publicado: (2018)

PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era
por: Chapman, M. John, et al.
Publicado: (2015)

Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk
por: Behr, Paulo Eduardo Ballvé, et al.
Publicado: (2018)

Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors
por: Pećin, Ivan, et al.
Publicado: (2017)

Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
por: Hwang, Hyeon Seok, et al.
Publicado: (2020)

PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis
por: Bodapati, Adi prasad, et al.
Publicado: (2023)

Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
por: Rymer, Jennifer A., et al.
Publicado: (2020)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Di’ao Xinxuekang Capsule Improves the Anti-Atherosclerotic Effect of Atorvastatin by Downregulating the SREBP2/PCSK9 Signalling Pathway
por: Liang, Jiyi, et al.
Publicado: (2022)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8mibnm55vqhvpf4pn81j8o1509